Fellowship · ATLANTA, GA
Sponsored by Emory University School of Medicine
Omalizumab for the Treatment of Multiple Food Allergies.
The New England journal of medicine · 2024 · 270 citations · Brian Vickery
EAACI guidelines on the diagnosis of IgE-mediated food allergy.
Allergy · 2023 · 258 citations · Brian Vickery
EAACI guidelines on the management of IgE-mediated food allergy.
Allergy · 2025 · 94 citations · Brian Vickery
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
The Lancet. Respiratory medicine · 2025 · 92 citations · Rachel Linnemann
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
The New England journal of medicine · 2023 · 105 citations · Brian Vickery
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
The Lancet. Respiratory medicine · 2025 · 44 citations · Ajay Kasi
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Annals of oncology : official journal of the European Society for Medical Oncology · 2021 · 260 citations · Ajay Kasi
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.
American journal of respiratory and critical care medicine · 2021 · 146 citations · Rachel Linnemann